Literature DB >> 18793571

Management of calcific uremic arteriolopathy (calciphylaxis) with a combination of treatments, including hyperbaric oxygen therapy.

M D Arenas1, M T Gil, M D Gutiérrez, T Malek, A Moledous, A Salinas, F Alvarez-Ude.   

Abstract

Calcific uremic arteriolopathy (CUA) is a rare but serious complication of end-stage renal disease presenting as painful cutaneous lesions and progressing to non-healing ulcers and gangrene. This syndrome is associated with calcium and phosphorus deposits within small arteries of the skin. The pathognomonic lesion is vascular calcification with intimal arterial hypertrophy and superimposed small-vessel thrombosis. The condition is being increasingly recognized and reported as a contributing factor to death in dialysis patients, with secondary infection and sepsis as the major cause of mortality. No standard treatment has been established for this syndrome. We present the therapeutic approach employed in two patients, which successfully resulted in healing of the lesions, using a combination of measures to control the factors potentially related to development of CUA and hyperbaric oxygen therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793571     DOI: 10.5414/cnp70261

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  9 in total

1.  Non-uraemic calciphylaxis successfully treated with pamidronate infusion.

Authors:  David H Truong; Marcus M Riedhammer; Kathya Zinszer
Journal:  Int Wound J       Date:  2018-11-04       Impact factor: 3.315

2.  Hyperbaric oxygen therapy in a patient with autosomal dominant polycystic kidney disease with a perinephritic abscess.

Authors:  Jorge Vega; Helmuth Goecke; Francisco Manriquez; Carlos Escobar; Max Escobar; Christian Videla; Mario Santamarina; Carlos Echeverria; Francisco Javier Guarda
Journal:  Clin Exp Nephrol       Date:  2010-10-01       Impact factor: 2.801

Review 3.  [Cutaneous calciphylaxis].

Authors:  U Wollina
Journal:  Hautarzt       Date:  2010-12       Impact factor: 0.751

Review 4.  Calcific uremic arteriolopathy: pathophysiology, reactive oxygen species and therapeutic approaches.

Authors:  Kurt M Sowers; Melvin R Hayden
Journal:  Oxid Med Cell Longev       Date:  2010 Mar-Apr       Impact factor: 6.543

5.  Calciphylaxis in Patients With Preserved Kidney Function.

Authors:  Natallia Maroz; Samer Mohandes; Halle Field; Zlata Kabakov; Richard Simman
Journal:  J Am Coll Clin Wound Spec       Date:  2015-08-07

6.  Calcific uremic arteriolopathy on multimodal combination therapy: still unmet goal.

Authors:  Usman Hammawa Malabu; Valli Manickam; George Kan; Susan Lynette Doherty; Kunwarjit Singh Sangla
Journal:  Int J Nephrol       Date:  2012-02-20

7.  Non-Uremic Calciphylaxis: A Rare Diagnosis with Limited Therapeutic Strategies.

Authors:  Felisbela Gomes; Pedro La Feria; Catarina Costa; Rita Santos
Journal:  Eur J Case Rep Intern Med       Date:  2018-12-27

8.  Treatment of Calciphylaxis in CKD: A Systematic Review and Meta-analysis.

Authors:  Suwasin Udomkarnjananun; Kitravee Kongnatthasate; Kearkiat Praditpornsilpa; Somchai Eiam-Ong; Bertrand L Jaber; Paweena Susantitaphong
Journal:  Kidney Int Rep       Date:  2018-10-09

9.  Update on cutaneous calciphylaxis.

Authors:  Uwe Wollina
Journal:  Indian J Dermatol       Date:  2013-03       Impact factor: 1.494

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.